STOCK TITAN

Klaviyo (NYSE: KVYO) investors price 6.5M-share secondary sale offering

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Klaviyo, Inc. disclosed that existing selling stockholders entered into an underwriting agreement with Barclays Capital Inc. to sell 6,500,000 shares of Klaviyo’s Series A common stock at a price of $30.01 per share. The stockholders also granted the underwriter a 30‑day option to purchase up to an additional 975,000 shares.

The transaction was registered on Klaviyo’s automatic shelf registration statement on Form S-3 and is expected to close on or about August 21, 2025. Klaviyo emphasizes that it will not receive any proceeds from the sale, which are payable to the selling stockholders, and notes that the underwriting agreement includes customary representations, covenants, closing conditions, and indemnification provisions.

Positive

  • None.

Negative

  • None.

Insights

Existing Klaviyo holders are selling 6.5M registered shares; the company itself raises no cash.

The disclosure describes an underwritten sale of 6,500,000 shares of Klaviyo Series A common stock by selling stockholders at $30.01 per share, with a 30‑day option for the underwriter to buy up to 975,000 additional shares. Because the filing states that the company did not receive any proceeds from the sale, this is a shareholder liquidity event rather than a primary capital raise.

The shares were registered under an automatic shelf on Form S-3, with the offering supported by preliminary and final prospectus supplements. From an investor standpoint, the key points are the size of the block being sold and that proceeds flow to selling stockholders, not to Klaviyo, while the underwriting agreement follows customary market terms, including standard indemnification and closing conditions.

FALSE000183583000018358302025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2025
Klaviyo, Inc.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
001-41806
(Commission File Number)
46-0989964
(I.R.S. Employer Identification Number)
125 Summer Street, 6th Floor, Boston, MA
   02110
(Address of principal executive offices)
(Zip Code)
(617) 213-1788
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Series A common stock, par value $0.001 per shareKVYONew York Stock Exchange
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐



Item 1.01. Entry into a Material Definitive Agreement.
On August 13, 2025, Klaviyo, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., as underwriter (the “Underwriter”), and the selling stockholders named therein (the “Selling Stockholders”).
Pursuant to the terms of the Underwriting Agreement, the Selling Stockholders sold an aggregate of 6,500,000 shares (the “Shares”) of the Company’s Series A common stock, par value $0.001 per share (“Series A common stock”), to the Underwriter at a price per share of $30.01 (the “Offering”). In addition, the Selling Stockholders granted the Underwriter an option to purchase, for a period of 30 calendar days from August 13, 2025, up to an additional 975,000 shares of Series A common stock. The Company did not receive any proceeds from the sale of the Shares by the Selling Stockholders.
The Offering was registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s automatic shelf registration statement on Form S-3 (File No. 333-285069) filed on February 19, 2025, as supplemented by a preliminary prospectus supplement filed August 13, 2025 and a final prospectus supplement filed August 15, 2025. The Underwriting Agreement contains customary representations, warranties and covenants, customary conditions to closing, indemnification obligations of the Company, the Selling Stockholders and the Underwriter, including for liabilities under the Securities Act and other obligations of the parties. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and are subject to limitations agreed upon by the contracting parties. A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit.
The Offering is expected to close on or about August 21, 2025. A copy of the legal opinion and consent of Goodwin Procter LLP relating to the Shares is attached as Exhibit 5.1 hereto.
Item 7.01. Regulation FD Disclosure.
On August 13, 2025, the Company issued a press release announcing the Offering. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
On August 15, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of this press release is furnished as Exhibit 99.2 to this report and is incorporated herein by reference.
The information in Exhibits 99.1 and 99.2 is intended to be furnished under Item 7.01 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.



Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
1.1
Underwriting Agreement, dated August 13, 2025, by and among Klaviyo, Inc., Barclays Capital Inc., as underwriter, and the Selling Stockholders.
5.1
Opinion of Goodwin Procter LLP.
23.1
Consent of Goodwin Procter LLP (contained in Exhibit 5.1).
99.1
Launch Press Release issued by Klaviyo, Inc., dated August 13, 2025.
99.2
Pricing Press Release issued by Klaviyo, Inc., dated August 15, 2025.
104
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 15, 2025
KLAVIYO, INC.
By:
/s/ Amanda Whalen
Name:
Amanda Whalen
Title:
Chief Financial Officer

FAQ

What did Klaviyo, Inc. (KVYO) announce in this 8-K filing?

Klaviyo reported that selling stockholders entered into an underwriting agreement with Barclays Capital Inc. to sell 6,500,000 shares of its Series A common stock at $30.01 per share, with an additional 975,000 shares available under a 30‑day option.

How many Klaviyo (KVYO) shares are being sold and at what price?

Selling stockholders sold 6,500,000 shares of Klaviyo’s Series A common stock to the underwriter at a price of $30.01 per share, and granted an option to purchase up to 975,000 additional shares within 30 calendar days from August 13, 2025.

Does Klaviyo receive any proceeds from this share sale?

No. The filing states that Klaviyo did not receive any proceeds from the sale of shares by the selling stockholders; the proceeds go to those stockholders.

How is this Klaviyo share sale registered with the SEC?

The offering is registered under the Securities Act pursuant to Klaviyo’s automatic shelf registration statement on Form S-3 (File No. 333-285069), supplemented by a preliminary prospectus supplement filed August 13, 2025 and a final prospectus supplement filed August 15, 2025.

When is the Klaviyo selling stockholder offering expected to close?

The offering of shares by the selling stockholders is expected to close on or about August 21, 2025, subject to the customary closing conditions in the underwriting agreement.

Who is the underwriter for the Klaviyo selling stockholder transaction?

Barclays Capital Inc. is the sole underwriter under the underwriting agreement with Klaviyo and the selling stockholders.

What additional documents are associated with this Klaviyo offering?

The filing lists the underwriting agreement as Exhibit 1.1, a legal opinion and consent from Goodwin Procter LLP as Exhibits 5.1 and 23.1, and two press releases related to the launch and pricing of the offering as Exhibits 99.1 and 99.2.
Klaviyo, Inc.

NYSE:KVYO

View KVYO Stock Overview

KVYO Rankings

KVYO Latest News

KVYO Latest SEC Filings

KVYO Stock Data

5.80B
141.92M
Software - Application
Services-prepackaged Software
Link
United States
BOSTON